Exploring new treatment strategies for patients with unresectable combined liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify novel treatment strategies for patients with unresectable combined hepatocellular-cholangiocarcinoma (CHC) by classifying patients into subtypes using artificial intelligence and multi-omics data. It will collect comprehensive data, including genomics, proteomics, and clinical records, from adult patients diagnosed with unresectable CHC. The study will utilize advanced data integration techniques to develop a large model for diagnosis and treatment recommendations, ultimately helping clinicians tailor therapies to specific patient subtypes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. age ≥18 years; diagnosis of CHC confirmed by histology or cytology;
2. patients with unresectable or metastatic CHC diagnosed on the basis of unresectable CHC who have received prior local therapy, systemic therapy, or a combination of both and have at least one measurable lesion (RECIST v1.1);
3. survival time ≥ 3 months;
4. ECOG PS 0-2;
5. Child-Pugh A/B.

Exclusion Criteria:

1. pregnant women, lactating women, and men and women of childbearing age who are unwilling or unable to use effective contraception.
2. history of other malignant tumors within the past five years, unless these tumors have been completely treated and have been free of active disease for five years prior to the first dose and are at low risk of recurrence.
3. fully treated carcinoma in situ with no evidence of disease.
4. history of gastrointestinal bleeding or significant bleeding tendency (e.g., with known active ulcers, fecal occult blood, etc.) within the past six months that precludes inclusion in the study; gastroscopy is required if there is persistent fecal occult blood.
5. substantial organ transplantation or bone marrow transplantation within two years prior to the first dose, or active autoimmune disease requiring systemic therapy.
6. other conditions that the investigator deems unsuitable for inclusion in the study. Inadequate information, such as incomplete data from laboratory tests, missing or poor quality imaging data, no prognostic information, etc., that the investigator considers unsuitable for inclusion in the study.

Where it's running

• Zhongda Hospital
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Principal investigator: Gao-Jun Teng, M.D — Zhongda hospital, Southeast university, Nanjing, China
• Study coordinator: Gao-Jun Teng, M.D
• Email: gjteng@vip.sina.com
• Phone: +86-02583272121

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Hepatic arterial infusion chemotherapy with camrelizumab and rivoceranib for advanced mixed hepatocellular‑cholangiocarcinoma

  This will test whether adding camrelizumab and rivoceranib to hepatic arterial infusion chemotherapy helps people with advanced mixed hepatocellular‑cholangiocarcinoma.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07105748

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.